AVTE Aerovate Therapeutics, Inc.

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price: $24.51

Increased by +0.49%
Dollar Volume: 2.06 M
ADR%: 8.5
Earnings Report Date (estimate): Nov 14, 22 (N/A)

Market Cap.: 603.07 M
Shares Float: 4.61 M
Shares Outstanding: 24.61 M

Beta: 0.00
Price / Earnings: 0.85
BPR: 310.81

20D Range: 21.48 27.37
50D Range: 14.33 30.79
200D Range: 10.52 30.79

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 14, 22	-0.56 Decreased by -115.38%	-0.50 Decreased by -12.00%
Aug 15, 22	-0.49 Increased by +97.94%	-0.45 Decreased by -8.89%
May 16, 22	-0.45	-0.28 Decreased by -60.71%
Mar 30, 22	-0.35	-0.31 Decreased by -12.90%
Nov 15, 21	-0.26	-0.26
Aug 16, 21	-23.80	-0.16 Decreased by -14.78 K%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	0.00 Decreased by N/A%	-13.59 M Decreased by -119.73%	Decreased by N/A% Decreased by N/A%
Jun 30, 22	0.00 Decreased by N/A%	-11.99 M Decreased by -107.64%	Decreased by N/A% Decreased by N/A%
Mar 31, 22	0.00 Decreased by N/A%	-10.91 M Decreased by -292.30%	Decreased by N/A% Decreased by N/A%
Dec 31, 21	0.00 Decreased by N/A%	-8.70 M Decreased by -137.23%	Decreased by N/A% Decreased by N/A%
Sep 30, 21	0.00 Decreased by N/A%	-6.18 M Decreased by -168.05%	Decreased by N/A% Decreased by N/A%
Jun 30, 21	0.00 Decreased by N/A%	-5.78 M Decreased by -162.26%	Decreased by N/A% Decreased by N/A%
Mar 31, 21	0.00 Decreased by N/A%	-2.78 M Decreased by -93.66%	Decreased by N/A% Decreased by N/A%
Dec 31, 20	0.00 -	-3.67 M -	Decreased by N/A% -

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.